In our program to develop Rac/Cdc42 inhibitors as anti-metastatic cancer agents, we first characterized EHop-016, which inhibits Rac activation by the GEF Vav with a half maximal inhibitory concentration (IC50) of 1 μM and inhibits tumor growth and metastasis in mouse models (25). Here, VAV1 is linked to cancer.